New projections call for the number of dementia cases in England and Wales to nearly double by 2040, reaching 1.7 million, a significant increase over prior estimates.
Cardiovascular risk factors and multi-comorbidity appear to play an important role in the association between atrial fibrillation and mild cognitive impairment.
Data from a small phase I study show significant clinical and biomarker activity of an investigational natural killer cell therapy in adults with AD, prompting a larger phase 2 trial.
Stopping metformin was linked to an increased risk for dementia diagnosis in a large cohort of adults with T2D, providing more evidence of the drug’s potential neuroprotective effects.